STAA
STAAR Surgical Company
$26.69
-2.16%
2026-05-08
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Key Fundamentals
Forward P/E
35.00
EPS (TTM)
$-1.62
ROE
-21.7%
Revenue Growth (YoY)
18.1%
Profit Margin
-33.6%
Debt/Equity
11.14
Price/Book
3.87
Beta
1.20
Market Cap
$1.34B
Avg Volume (10D)
739K
Recent Breakout Signals
No recent breakout signals detected for STAA.
Recent Price Range (60 Days)
60D High
$28.17
60D Low
$15.59
Avg Volume
1.2M
Latest Close
$26.69
Get breakout alerts for STAA
Sign up for Breakout Scanner to receive daily notifications when STAA triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
STAAR Surgical Company (STAA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors STAA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. STAA operates in the Healthcare sector within the Medical Instruments & Supplies industry. Data is provided for informational purposes only and does not constitute financial advice.